Zacks small cap research.
Nov 10, 2023 · Earnings Update. • Cash and cash equivalents were $1.5 million at the end of 3Q, down from $3.8 million at the end of 1Q. o During 3Q, Ensysce (NASDAQ:ENSC) completed a convertible note financing offer that netted the company roughly $560,000 before fees and offering expenses, with the potential for another $1.13 million upon “satisfaction ...
By Brad Sorensen, CFA OTC:FRXIF READ THE FULL FRXIF RESEARCH REPORT Demand continues to increase for a flame retardant that doesn’t have toxic chemicals and the Nofia product from FRX Innovations (OTC:FRXIF), an eco-friendly flame retardant solution, is the perfect solution. Studies previously cited by the FRX note that over 60% of fire-retardant plastic formulations are based onBy Brad Sorensen, CFA OTC:CLMEF READ THE FULL CLMEF RESEARCH REPORT We are reiterating are positive view on Calima Energy (OTC:CLMEF) and urging investors to take a look at a company with an in-demand asset that is well run, cares about shareholders, and is trading well below our conservative valuation of $0.55/share. …By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT We are initiating coverage of Abeona Therapeutics Inc. (NASDAQ:ABEO) with a valuation of $10.00. Abeona is a biopharmaceutical company developing cell and gene therapies for rare genetic diseases. Its lead clinical program, EB-101, is an autologous cell therapy in development for the treatment of recessive dystrophic epidermolysisThe following disclosures relate to relationships between Zacks Small-Cap Research ( Zacks SCR ), a division of Zacks Investment Research ( ZIR ), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe. ANALYST DISCLOSURES. Zacks SCR Analysts hereby certify that the view expressed in this research report or article ...
06/12/2023. UHAL: U-Haul Holding Company Reports Financial Results for Fiscal 2023; Demand for truck rentals slowed in the second half of FY2023. Management aspires to hold the market share gains and has expectations that the self-moving market will stabilize in FY2024. 06/08/2023.1. Source: Created by Zacks Small Cap Research Analysts. By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT BALANCE Interim Results On June 2, 2021, Protalix and development partner, Chiesi Global Rare Diseases, provided an update regarding clinical development of Protalix’ candidate pegunigalsidase alfa (PRX …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …
Aug 24, 2021 · By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Update on Phase 1 Trial of EPI-7386 ESSA Pharma Inc. (NASDAQ:EPIX) is currently conducting a Phase 1 clinical trial of EPI-7386 in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed on two or more systemic therapies, including at least one second generation anti-androgen
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …LEXX: GLP-1s’ Sweet Opportunity. Lexaria Bioscience Corporation (NASDAQ:LEXX) reports fiscal full year 2023 results along with program updates, new deals and a small capital raise since the third quarter report in August. The company announced that the investigational new drug (IND) application would be delayed on account of a supplier. OTC:NEXCF. READ THE FULL NEXCF RESEARCH REPORT. Nextech AR’s (OTC:NEXCF) Q3 report showed a rapid uptake of its AR 3D model subscription business which grew 192% sequentially. It plans to deliver $700,000 worth of models to Amazon (we believe) alone in Q4 and the business continues to thrive. Just as …Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research. Read full article. Gain Therapeutics, Inc. December 4, 2023 at …Aug 24, 2023 · By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update HyBryte™ Expanded Treatment Trial Underway On August 10, 2023, Soligenix, Inc. (NASDAQ:SNGX) announced the start of the investigator-initiated study that is designed to examine the expanded treatment, including up to 12 months of treatment, with HyBryte in patients with early-stage cutaneous T cell lymphoma ...
Zacks Small-Cap Research Lisa Thompson 312-265-9154 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 September 1, 2021 Raising …
David Bautz, PhD, Senior Analyst for Zacks Small-Cap Research, with 9 years of direct experience in the securities and investment industry. David’s research articles have been posted extensively on Yahoo Finance News and throughout life sciences social media circles. Prior to joining Zacks in 2014, David was an NRSA postdoctoral fellow ...
Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted results from its Ongoing Research of Cytisinicline for Addiction, Vaping (ORCA-V1) trial and hosted a conference call for investors on April 20, 2023. The Phase II ORCA-V1 trial was conducted to measure the safety and effectiveness of 3 mg of cytisinicline dosed three times daily for 12 weeks ...ORMP: Data from NASH Phase 2 Study – Positive Takeaways . 11/21/2022. Download (opens in new window)Gain Therapeutics, Inc. today announced that the Company’s Chief Executive Officer, Matthias Alder, will participate in a fireside chat, hosted by FORCE Family Office, …'Who needs breadth when we have Nvidia's beat?': We've been here before, and I can tell you it lasts longer than it should. Let's look at charts and indicators, past and present....NVDA We're in that part of the cycle wh...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Third Quarter Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported 3Q:23 results on November 13, 2023 via its filing of Form 10-Q with the SEC. Since the filing of the second quarter 10-Q in mid-August, the company has finished compiling and submitting its investigational new drug (IND)Zacks Rank N/A BIOR: Precision Release – Surgical Strike on the GI Tract Zacks Small-Cap Research Joh Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. …
Oct 31, 2023 · Fund Description. The fund was incepted in May 2000 and is managed by Franklin Advisers. The objective of this fund is long-term capital growth. The fund invests at least 80% of its net assets in ... A conference call with investors and analysts was held immediately following the release. 2Q:23 revenues of $3.6 million were ahead of our initial estimates and matched revised company guidance. Net loss per share was ($1.03). Management reiterated its outlook of revenues between $14.0 and $15.0 million in 2023.Nov 18, 2022 · OTC:NEXCF. READ THE FULL NEXCF RESEARCH REPORT. Nextech AR’s (OTC:NEXCF) Q3 report showed a rapid uptake of its AR 3D model subscription business which grew 192% sequentially. It plans to deliver $700,000 worth of models to Amazon (we believe) alone in Q4 and the business continues to thrive. Just as importantly, the company has reduced its ... SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.ZACKS SMALL/MID CAP ETF. The Zacks Small/Mid Cap ETF seeks to generate consistent and sustainable returns while minimizing the risk of capital …Genasys (. GNSS Quick Quote. GNSS - Free Report) has an Earnings ESP of +21.74% and a Zacks Rank #2. GNSS is scheduled to release fourth-quarter fiscal 2023 …By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Expect no disruption from management change; increased emphasis on studying Hemopurifier® in oncology likely… Aethlon Medical (NASDAQ:AEMD) appointed CFO James Frakes as interim CEO. We expect no disruption as a result of the management change – Mr. Frakes has been with Aethlon since 2008 knows the company well, in our view.
The details of 2Q 2023: • Revenue for the quarter came in at $1,480,388, which was more than double the revenue seen in the previous quarter of just over $625,000. • FRX posted a quarterly loss of $0.02 per share, slightly ahead of our estimates due largely to an improvement in the gross margin. • Gross margins improved to a gain of ...SCR Premium. Receive Initiation Reports PROMPTLY as they are sent out to the marketplace. Access the FULL REPORT CATALOG on any company we cover. Receive the DAILY ALERT EMAIL, containing all of the day's updates, around 5 p.m. EST. Access to REAL-TIME EMAIL ALERTS for any companies covered by Zacks SCR analysts.. …
Free Weekly Digest. Zacks Small Cap Research covers more than 100 small- and micro-cap companies that are under-followed or under-valued by Wall Street. Our analysts cover all major sectors...When it comes to maintaining the aesthetics and functionality of your wheels, OEM wheel center caps play a crucial role. These small but significant accessories not only add a touch of style to your vehicle’s appearance but also provide ess...A division of Zacks Investment Research, Zacks Small-Cap Research covers small and micro-cap companies under-followed by Wall Street. Our in-depth fundamental research reports, commentary ...Dec 22, 2022 · By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Phase 2b Data for EB01 in January 2023 Edesa Biotech, Inc. (NASDAQ:EDSA) is currently conducting a double blind, placebo controlled trial to evaluate the safety and efficacy of 2.0% EB01 cream in approximately 170 evaluable subjects in total suffering from chronic allergic contact dermatitis (ACD) (NCT03680131). On November 19, 2023, MediciNova, Inc. (NASDAQ:MNOV) announced new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …By David Bautz, PhD NASDAQ:TNXP READ THE FULL TNXP RESEARCH REPORT Business Update In-House Research Capabilities Bolstered Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has increased its in-house research capabilities with the purchase, construction, and planned construction of multiple research centers. These facilities will allow the company to have better control over the earlySimilar to other regions, penetration into the near 22,000 low risk SCCHN cases is expected to start at 3% and rise to 30% by year six then market share stabilization and declines in 2033 and 2034. The final geography that we include in our DCF model is the UK. According to Cancer Research UK, there are about 12,400 head and neck cancers.
Zacks Small Cap Research Coverage Universe. For access to our most recent reports, please click on the links below. To join our paid real time email service please enter your email address and select the companies you would like to follow. An email will be sent to you for payment and setup instructions. Special Situations / Steven Ralston, CFA.
Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research. Read full article. Gain Therapeutics, Inc. December 4, 2023 at …
The following slide gives an overview of the planned early stage clinical trials for CF-370 following submission of the IND, which we expect to occur in the third quarter of 2023. While a Phase 2 proof-of-concept trial is currently planned in patients with cystic fibrosis, the broad spectrum activity of CF-370 means it could likely be used for ...Frequent use can lead to cannabis use disorder, characterized by withdrawal symptoms, cravings, and difficulty quitting, which can have a significant impact on one's daily life. Additionally, smoking or vaping THC can harm lung health and may increase the risk of respiratory issues. Furthermore, THC can impair motor coordination and judgment ...About Zacks Small-Cap Research Zacks/SCR prepares company-sponsored, independent research and related content for distribution through a multitude of investor and media channels, both traditional ...The TSP-21-G form is the loan agreement form individuals sign when they borrow against their Thrift Savings Plan accounts, according to the U.S. Government Publishing Office. TSP loans are only available to current military and federal empl...When it comes to wheels, one small but important component that often goes unnoticed is the wheel center cap. These caps not only add a touch of style to your vehicle’s wheels but also serve several practical functions.By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Advancing Multiple Clinical Trials in 2023 ESSA Pharma Inc (NASDAQ:EPIX) is developing EPI-7386 as a treatment for prostate cancer. It is a member of a novel class of compounds known as ‘anitens’, which specifically target the androgen …INXDF: INXDF is Changing the Digital Financial World. INX Digital (OTCQB:INXDF) is a company that provides a regulated platform where verified customers can trade cryptocurrencies and security tokens on a secure and around the clock basis. The security token market appears poised to explode and INX is the only company to this …By Brad Sorensen, CFA OTC:PBSV READ THE FULL PBSV RESEARCH REPORT Pharma-Bio Serv (OTC:PBSV) announced 2Q 2023 results. The headline showed that earnings per share of $0.02 were inline with our estimates, driven by the continued impressive improvement in gross margin on sales revenue by another 5% in the quarter …$30.59 USD -0.17 (-0.55%) Zacks MF Rank NA View All Zacks Mutual Fund Rank #1's Zacks Mutual Funds Categories » Small Cap Blend Latest Performance as of …$31.77 USD -0.10 (-0.31%) Zacks MF Rank NA View All Zacks Mutual Fund Rank #1's Zacks Mutual Funds Categories » Small Cap Blend Latest Performance as of Oct 31, 2023 * Annual for three...
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …By John Vandermosten, CFA NYSE:NHWK READ THE FULL NHWK RESEARCH REPORT NightHawk Biosciences, Inc. (NYSE:NHWK) reported third quarter results on November 14, 2022 in a press release and in its Form 10-Q filing. It has been a whirlwind year for the company as it made an acquisition, expanded its manufacturing …Research and development expenses in the 3rd quarter of 2023 were $469,000 which was similar to R&D expenses in the 3rd quarter of 2022 of $468,000. R&D expenses include the use of third-party contractors for further R&D activities, the performance of usability studies for the PressureSafe device, and non-cash expenses relating to stock-based ...Instagram:https://instagram. jim cramer nvidia stock1979 1 dollar coinairleaseprivate dental insurance arizona Zacks Investment Research has three different main subscription plans: Zacks Premium, Zacks Investor Collection, and Zacks Ultimate. Zacks Premium costs …The details of 2Q 2023: • Revenue for the quarter came in at $1,480,388, which was more than double the revenue seen in the previous quarter of just over $625,000. • FRX posted a quarterly loss of $0.02 per share, slightly ahead of our estimates due largely to an improvement in the gross margin. • Gross margins improved to a gain of ... best real estate to invest in 2023stock oke SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Fund Description. The fund was incepted in May 2000 and is managed by Franklin Advisers. The objective of this fund is long-term capital growth. The fund invests at least 80% of its net assets in ... tesla stocks prediction By Thomas Kerr, CFA NASDAQ:UXIN READ THE FULL UXIN RESEARCH REPORT On December 30th, Uxin (NASDAQ:UXIN) reported fiscal 2nd quarter operating and financial results for the three-month period ending September 30, 2022. Total revenues increased to $87 million which was a 1.2% increase from the fiscal 1st quarter and a …The NELL-1 technology is the centerpiece of what Bone Biologics (NASDAQ:BBLG) is developing. It was developed by UCLA TDG and Bone holds the exclusive worldwide rights to that technology. NELL-1 has been reviewed positively in over 45 peer reviewed publications demonstrating technological viability. NELL-1 has shown spine fusion effectiveness ...